Inclusion Criteria:

- Written informed consent

- Age ≥ 18 years

- Histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) with
lymphatic (N-stage 2-3) and/or distant metastases (M-stage 1) not amenable to
definitive regional/local therapy

- Progression of tumor disease after platinum containing systemic chemotherapy for
advanced or metastatic disease

- Eastern Cooperative Oncology Group (ECOG) performance status of 1

- estimated minimal life expectancy of 3 months at screening

- At least one measurable tumor lesion according to RECIST 1.1 criteria

- Adequate organ system function at screening

- Adequate contraception

Exclusion Criteria:

- More than 1 prior chemotherapy, biologic therapy or hormonal therapy within 14 days
prior to the first dose of study medication

- Prior malignancy within 5 years prior to inclusion (exception: successfully treated
basal cell carcinoma or in situ carcinoma)

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding within 28 days prior to beginning study treatment, e.g

- Active peptic ulcer disease

- Known intraluminal metastatic lesion/s with risk of bleeding

- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
gastrointestinal conditions with increased risk of perforation

- History of abdominal fistula, gastrointestinal perforation, or intraabdominal
abscess

- Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product, e.g.

- Malabsorption syndrome

- Major resection of the stomach or small bowel

- Active infection requiring antibiotics within 14 days before registration

- Corrected QT interval (QTc) > 480 msecs using Bazett's formula at screening

- Screening-electrocardiogram (ECG) with any significant modifi¬cations suggesting a
high risk of occurrence of an acute clinical event (such as signs of angina pectoris,
high risk arrhythmia etc.)

- History of one or more of the following cardiac / cardiovascular conditions within
the past 6 months before registration:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- NYHA Class II, III or IV congestive heart failure

- Uncontrolled cardiac arrhythmia

- Poorly controlled hypertension, defined as systolic blood pressure (SBP) of ≥140 mmHg
or diastolic blood pressure (DBP) of ≥ 90 mmHg

- History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
before registration

- Peripheral neuropathy grade ≥ 2 (NCI CTC v3.0)

- Unstable diabetes mellitus

- Uncontrolled hypercalcaemia > 2.9 mmol/L

- Prior major surgery or trauma within 28 days prior to registration and/or presence of
any non-healing wound, fracture, or ulcer (procedures such as catheter placement not
considered to be major)

- Evidence of active bleeding e.g. GI bleeding or bleeding diathesis at screening.

- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

- Hemoptysis with bleeding of > 2.5 mL within 8 weeks before registration

- Any serious and/or unstable pre-existing medical, psychiatric/psychological,
familial, sociological, geographical or other condition that could interfere with
subject's safety, provision of informed consent, or compliance to study procedures

- prior to the first dose of study drug and for the duration of the study

- Radiation, surgery or tumor embolization or any investigational treatment within 14
days prior to the first dose of study medication

- Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or
progressing in severity, except nausea, vomiting, alopecia

- ASA 4

- Pre-treatment with Pazopanib or Vinflunine

- Pregnancy or lactation